Last updated: 02/04/2020 18:50:08

PAZOPANIB FOR THE FIRST AND SECOND LINE TREATMENT OF ADVANCED STAGE PATIENTS WITH GOOD TO INTERMEDIATE RISK RENAL CELL CARCINOMIA: A COST MINIMIZATION ANALYSIS

GSK study ID
117348
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: PAZOPANIB FOR THE FIRST AND SECOND LINE TREATMENT OF ADVANCED STAGE PATIENTS WITH GOOD TO INTERMEDIATE RISK RENAL CELL CARCINOMIA: A COST MINIMIZATION ANALYSIS
Trial description: The indirect statistical comparisons between pazopanib and the comparators will be performed using two unique approaches. The first indirecrt comparsion will be a meta-regression analysis on all the relevant clinical outcomes and the number of withdrawals caused by adverse drug reactions reported in the trials.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Progression Free Survival

Timeframe: 24 weeks

Secondary outcomes:

Overall Survival

Timeframe: 5 years

Interventions:
  • Drug: pazopanib
  • Drug: Sorafenib
  • Drug: interferon
  • Drug: everolimus
  • Drug: Sunitinib
  • Drug: temsirolimus
    • Enrollment:
    0
    Primary completion date:
    2013-26-08
    Observational study model:
    Other
    Time perspective:
    Retrospective
    Clinical publications:
    Not applicable
    Medical condition
    Carcinoma, Renal Cell
    Product
    pazopanib
    Collaborators
    Augmentium Pharma Consulting
    Study date(s)
    November 2010 to August 2013
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    none
    • Clinical trials with at least 50 patients enrolled into each arm which consisted of either active therapy or placebo.
    • Adult patients
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Clinical trials with at least 50 patients enrolled into each arm which consisted of either active therapy or placebo.
    • Adult patients
    • Patients must have been treatment naive or had received only one prior cytoline-based therapy.
    • The promary and secondary endpoint must have been progression free survival and overal survival.

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2013-26-08
    Actual study completion date
    2013-26-08

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website